Maryland Senate Bill SB575

Maryland 2023 Regular Session

• Introduced: 2/6/23
• Refer: 2/6/23

Caption

Drug Manufacturers - Drug Take-Back Programs (Take It Back Maryland Act)

Impact

The implementation of SB575 is expected to significantly impact laws governing drug disposal in Maryland. By requiring manufacturers to take an active role in drug take-back initiatives, the bill not only aims to reduce the risk of drug misuse and environmental pollution but also promotes public awareness regarding safe disposal practices. The bill places clear accountability on manufacturers who are now legally obligated to ensure the safe disposal of the drugs they produce and sell in the state.

Summary

Senate Bill 575, known as the Take It Back Maryland Act, mandates that manufacturers of certain drugs in Maryland establish or participate in drug take-back programs. The primary objective of this bill is to provide a structured method for safely disposing of drugs, including prescription and non-prescription medications, to safeguard public health and the environment. Each manufacturer is required to either operate their own take-back program or collaborate with a drug take-back organization or the Maryland Department of Health in conjunction with the Department of the Environment to fulfill this responsibility.

Contention

There were notable discussions regarding the responsibilities placed on manufacturers and the potential costs associated with running a drug take-back program. Supporters of the bill argue that the long-term benefits in terms of public health and reduced environmental hazards outweigh these costs. However, some critics express concern about the financial burden that these requirements could impose on manufacturers, particularly smaller ones, suggesting that this could lead to increased prices for consumers as companies look to cover their operational costs associated with such programs.